Accelerated waning of the humoral response to COVID-19 vaccines in obesity
Agatha A van der Klaauw,Emily C Horner,Pehuén Pereyra-Gerber,Utkarsh Agrawal,William S Foster,Sarah Spencer,Bensi Vergese,Miriam Smith,Elana Henning,Isobel D Ramsay,Jack A Smith,Stephane M Guillaume,Hayley J Sharpe,Iain M Hay,Sam Thompson,Silvia Innocentin,Lucy H Booth,Chris Robertson,Colin McCowan,Steven Kerr,Thomas E Mulroney,Martin J O'Reilly,Thevinya P Gurugama,Lihinya P Gurugama,Maria A Rust,Alex Ferreira,Soraya Ebrahimi,Lourdes Ceron-Gutierrez,Jacopo Scotucci,Barbara Kronsteiner,Susanna J Dunachie,Paul Klenerman,PITCH Consortium,Adrian J Park,Francesco Rubino,Abigail A Lamikanra,Hannah Stark,Nathalie Kingston,Lise Estcourt,Heli Harvala,David J Roberts,Rainer Doffinger,Michelle A Linterman,Nicholas J Matheson,Aziz Sheikh,I Sadaf Farooqi,James E D Thaventhiran
DOI: https://doi.org/10.1038/s41591-023-02343-2
Abstract:Obesity is associated with an increased risk of severe Coronavirus Disease 2019 (COVID-19) infection and mortality. COVID-19 vaccines reduce the risk of serious COVID-19 outcomes; however, their effectiveness in people with obesity is incompletely understood. We studied the relationship among body mass index (BMI), hospitalization and mortality due to COVID-19 among 3.6 million people in Scotland using the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) surveillance platform. We found that vaccinated individuals with severe obesity (BMI > 40 kg/m2) were 76% more likely to experience hospitalization or death from COVID-19 (adjusted rate ratio of 1.76 (95% confidence interval (CI), 1.60-1.94). We also conducted a prospective longitudinal study of a cohort of 28 individuals with severe obesity compared to 41 control individuals with normal BMI (BMI 18.5-24.9 kg/m2). We found that 55% of individuals with severe obesity had unquantifiable titers of neutralizing antibody against authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus compared to 12% of individuals with normal BMI (P = 0.0003) 6 months after their second vaccine dose. Furthermore, we observed that, for individuals with severe obesity, at any given anti-spike and anti-receptor-binding domain (RBD) antibody level, neutralizing capacity was lower than that of individuals with a normal BMI. Neutralizing capacity was restored by a third dose of vaccine but again declined more rapidly in people with severe obesity. We demonstrate that waning of COVID-19 vaccine-induced humoral immunity is accelerated in individuals with severe obesity. As obesity is associated with increased hospitalization and mortality from breakthrough infections, our findings have implications for vaccine prioritization policies.